News | January 27, 2022
Moderna working on Omicron-specific booster candidate
This will evaluate the immunogenicity, safety, and reactogenicity of a single booster dose in adults aged 18 years and older
This will evaluate the immunogenicity, safety, and reactogenicity of a single booster dose in adults aged 18 years and older
Startup receives US $ 5 million in first round of funding
The 12-month alpha-testing phase will bring together ZEISS R&D, three academic collaborators, and three pharmaceutical industry partners
The goal is to better support drug developers as programs move from laboratory research into clinical trials
CDSCO-cleared BSM-5700 series targets ICU, NICU, ER, OR and digital health integration under ABDM
Strategic expansion strengthens CDMO’s support for biotech and pharma innovators across the Asia-Pacific region
Paves the way for next-gen ultra-precise gas sensing
A major push to sharpen the future of cancer treatment is underway
Outlines 1,500-member internal cadre, digital regulatory system, and faster SEC-led reviews
At the centre of this shift is Eli Lilly and Company, whose latest investments in China and Japan are helping redefine the next phase of GLP-1 supply strategy
Subscribe To Our Newsletter & Stay Updated
